Herpes

Herpes Zoster News

Experimental Drug RGN-259 Promotes Healing In Patients With Non-Healing Corneal Ulcers - Four Patients Treated Under ...Tuesday, November 18, 2008 @ 4:08PMREGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that its ophthalmic drug candidate, RGN-259, was used to treat four neurotrophic keratitis patients with non-healing eye ulcers caused primarily by the herpes zoster virus under a "Compassionate Use" IND (Investigational New Drug application).

Multiplex Assay for Virus DetectionTuesday, November 18, 2008 @ 2:13PMMultiplex PCR based assay for the combined detection and diagnosis of Herpes viruses in patient samples.

Integrating Adult Vaccines into Your Routine CareMonday, November 17, 2008 @ 6:20AM(ARA) - Every year, nearly 50,000 Americans, mostly adults, die from diseases that vaccination can prevent and millions more need to be hospitalized, get too sick to care for loved ones, like children or elderly parents, and are forced to miss work.

Inhibitex to Present at Two Investor Conferences in November 2008Wednesday, November 5, 2008 @ 5:50PMInhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced today that Russell H. Plumb, president and chief executive officer of Inhibitex, Inc., is scheduled to present at the following two conferences in November 2008:

Inhibitex to Present at Two Investor Conferences in November 2008Wednesday, November 5, 2008 @ 5:48PMInhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on developing products to treat

Inhibitex to Present at Two Investor Conferences in November 2008Wednesday, November 5, 2008 @ 5:30PM ATLANTA----Inhibitex, Inc. , a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced today that Russell H. Plumb, president and chief executive officer of Inhibitex, Inc., is scheduled to present at the following two conferences in November 2008: The Rodman & Renshaw Annual Global Investment Conference on November 11, 2008 at 3:15 ...

My Pharmiweb.comThursday, October 30, 2008 @ 8:10AMAbbott Park, Illinois (NYSE: ABT) — New data show half of patients with moderate to severe early rheumatoid arthritis showed no progression of joint damage at five years.